Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

OM:SAVE
OM:SAVECapital Markets

Why Nordnet (OM:SAVE) Is Up 6.9% After Strong FY 2025 Earnings And Dividend Proposal

Nordnet AB (publ) reported past fourth-quarter 2025 net income of SEK 774 million and full-year net income of SEK 3.02 billion, with basic earnings per share rising to SEK 11.83 from SEK 10.86 a year earlier. Alongside these results, the Board intends to propose a SEK 8.60 per share dividend for 2025, signalling confidence in the company’s earnings power and cash-generation capacity. With this combination of higher earnings and a proposed SEK 8.60 dividend, we’ll explore how Nordnet’s...
NYSE:DAR
NYSE:DARFood

Why Darling Ingredients (DAR) Is Up 6.8% After Renewable Diesel Drives Surprise Quarterly Profit – And What's Next

In its most recent quarter, Darling Ingredients reported US$55 million in net income despite a full-year operating loss of US$156 million, with the renewable diesel segment alone contributing US$92 million of income. Management highlighted sequential improvements and voiced renewed confidence in both renewable diesel and core ingredients, signaling a potential inflection in how the business mix supports overall earnings resilience. Next, we will examine how the renewable diesel segment’s...
TSE:8060
TSE:8060Electronic

Will Canon Marketing Japan's (TSE:8060) Higher ¥170 Dividend and 40% Payout Target Change Its Narrative

Canon Marketing Japan Inc. recently reported full-year 2025 results, with sales of ¥679,799 million and net income of ¥41,458 million, while approving a higher year-end dividend of ¥100 per share, bringing the total annual dividend to ¥170. The company also issued 2026 earnings guidance and reaffirmed a dividend policy targeting a consolidated payout ratio of around 40% or above, underscoring how profit distribution is being balanced against future investment needs and cash flow...
TSE:6702
TSE:6702IT

Did Stronger Results, Higher Dividend And New AI Role Just Shift Fujitsu's (TSE:6702) Investment Narrative?

Fujitsu Limited reported significantly stronger results for the nine months to December 31, 2025, raised its full-year earnings guidance, and announced a planned increase in its annual dividend forecast from JPY 15.00 to JPY 35.00 per share, following Board discussions on January 29, 2026. Alongside the financial updates, a new U.S. Department of Energy Argonne National Laboratory partnership with RIKEN, Fujitsu and NVIDIA highlights Fujitsu’s role in next-generation AI and high-performance...
SEHK:9863
SEHK:9863Auto

A Look At Leapmotor (SEHK:9863) Valuation After Clarifying Independent Domestic Share Subscription

Zhejiang Leapmotor Technology (SEHK:9863) has detailed a domestic share subscription under its general mandate, highlighting state owned Jinyi High-Tech as an independent, non connected investor and stressing compliance with Hong Kong listing rules. See our latest analysis for Zhejiang Leapmotor Technology. At a latest share price of HK$42.42, Zhejiang Leapmotor Technology’s short term share price returns, including a 30 day share price return of a 14.41% decline and a 90 day share price...
SEHK:1729
SEHK:1729Electrical

Assessing Time Interconnect Technology (SEHK:1729) Valuation After New Board And MedTech Leadership Appointments

Time Interconnect Technology (SEHK:1729) has reshaped its leadership with three new board appointments, bringing its Chief Operating Officer, its Executive Vice President for MedTech, and a healthcare academic leader formally into director roles. See our latest analysis for Time Interconnect Technology. The leadership reshuffle comes after a period of mixed share price momentum, with a 1 day share price return of 4.59% from a last close of HK$15.5, set against a 30 day share price return of...
NYSE:CF
NYSE:CFChemicals

What CF Industries Holdings (CF)'s Low‑Carbon Fertilizer Pilot and Dividend Move Means For Shareholders

CF Industries Holdings, Inc. recently declared a US$0.50 per share dividend payable on February 27, 2026, and expanded its collaboration with POET and leading agricultural cooperatives on a pilot low-carbon fertilizer supply chain across several Midwestern states. This initiative links certified low-carbon ammonia from CF Industries’ Donaldsonville Complex directly to corn and ethanol production, potentially reshaping how fertilizer carbon intensity is tracked across the full agricultural...
SEHK:1672
SEHK:1672Biotechs

Assessing Ascletis Pharma (SEHK:1672) Valuation After Positive Acne Data And Denifanstat NDA Acceptance

Ascletis Pharma (SEHK:1672) is back in focus after reporting favorable long term safety data from its Phase III acne drug denifanstat and confirming that China’s regulator has accepted its New Drug Application. See our latest analysis for Ascletis Pharma. The acne data and NDA progress come on the back of an active few weeks across its GLP 1 and metabolic pipeline. The share price has moved accordingly, with a 30 day share price return of 19.79% and 90 day share price return of 40.67%, adding...
ASX:OCL
ASX:OCLSoftware

Objective (ASX:OCL) Authorizes 10% Buyback Capacity Is Its Capital Strategy Entering a New Phase?

In January 2026, Objective Corporation Limited (ASX:OCL) authorized a share repurchase program allowing the company to buy back up to 9,590,176 shares, or 10% of its 95,901,766 issued shares, through February 5, 2027. This sizeable buyback capacity gives Objective meaningful flexibility to adjust its capital structure and potentially concentrate ownership among remaining shareholders over time. We’ll examine how Objective’s decision to authorize repurchases of up to 10% of its share base...
NYSE:MCK
NYSE:MCKHealthcare

Does European Exit And Steady Dividend Shift McKesson’s Capital Allocation Story For Investors (MCK)?

McKesson Corporation has completed the sale of its retail and distribution businesses in Norway, the final step in its exit from European operations, and also declared a regular dividend of US$0.82 per share payable on April 1, 2026 to shareholders of record on March 2, 2026. This exit frees up capital and management attention for McKesson to concentrate on its core growth platforms in Oncology, Multispecialty, and Biopharma Services, while its ongoing dividends underscore a continued...
ASX:SOM
ASX:SOMMedical Equipment

ASX Penny Stocks To Watch In February 2026

The Australian market is facing a challenging start to the week, with an anticipated 0.8% drop in futures as investors brace for a potential interest rate hike by the Reserve Bank and react to international economic developments. In this climate, identifying promising investment opportunities requires careful consideration of financial health and growth potential. Penny stocks, though often overlooked, can still offer unique opportunities for those willing to explore smaller or newer...
NYSE:FDX
NYSE:FDXLogistics

FedEx (FDX) Valuation Check After Earnings Beat Cost Cuts And Planned Freight Spin Off

Investor confidence in FedEx (FDX) has been rising due to better-than-expected earnings, cost reduction efforts, an optimistic management outlook, and plans to spin off the freight business. See our latest analysis for FedEx. Those earnings and cost cuts are showing up in the share price action, with a 27.38% 90 day share price return and a 24.54% 1 year total shareholder return suggesting that momentum has been building rather than fading. If FedEx’s recent move has caught your eye, this can...
NasdaqGM:RDNT
NasdaqGM:RDNTHealthcare

Assessing RadNet (RDNT) Valuation After Recent Share Price Softness

Event overview and why RadNet is on investors’ radar RadNet (RDNT) has caught investor attention after recent trading performance. The stock is down 0.9% over the past week and 10% over the past 3 months, prompting closer scrutiny of its fundamentals. See our latest analysis for RadNet. Looking beyond the recent pullback, RadNet’s share price return over the past 3 months has softened. Its 1 year total shareholder return of 7.1% and very large 3 and 5 year total shareholder returns point to...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans

Olema Pharmaceuticals (OLMA) is back on trader watchlists after recent analyst commentary around its breast cancer pipeline and management’s confirmation that key clinical milestones remain on schedule through 2026. See our latest analysis for Olema Pharmaceuticals. At a share price of US$25.72, Olema has eased back slightly in the last session, but its roughly 205% 90 day share price return and very large 1 year total shareholder return suggest momentum has been building as investors weigh...